Roy Herbst discusses the ADAURA trial investigating the postoperative use of osimertinib in patients with EGFR-mutated non-small-cell lung cancer, and comments on the potential for using it in the neoadjuvant setting (4:55).
03-06-2020 | ASCO 2020 | Conference coverage | Video